文献速递免疫规划慢病防控与筛查卫生政策与健康促进

2023-2024年度美国65岁及以上医疗保险受益人接种流感疫苗后健康结局的安全性监测

Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older.
PubMed 文献 · Vaccine · 2025-04-08

本研究采用自对照病例系列分析,评估2023-2024年度流感疫苗在65岁及以上美国医疗保险受益人中接种后发生过敏反应、脑炎/脑脊髓炎/急性播散性脑脊髓炎、吉兰-巴雷综合征、横贯性脊髓炎、出血性卒中、非出血性卒中、短暂性脑缺血发作(TIA)及非出血性卒中/TIA的风险。共观察20,258,006名接种者,多数结局未见统计学显著风险升高,但高剂量疫苗受试者的非出血性卒中/TIA复合结局在22-42天风险窗内风险轻微升高,结论认为流感疫苗的获益可能大于本研究所发现的风险。

要点

  • 共纳入20,258,006名65岁及以上流感疫苗接种者,采用自对照病例系列分析评估安全性。
  • 过敏反应、脑炎/脑脊髓炎(含ADEM)、吉兰-巴雷综合征、出血性卒中、横贯性脊髓炎未见统计学显著风险升高。
  • 高剂量疫苗受试者的非出血性卒中/TIA复合结局在22-42天风险窗内风险轻微升高,按服务付费人群IRR为1.07(95%CI 1.01,1.14)。

核心结论

  • 既往研究确立的季节性流感疫苗获益可能大于本研究所发现的风险。
  • 卒中结局的轻微风险升高需结合流感疫苗接种的已知获益仔细考量。

研究设计与样本

  • 采用自对照病例系列(SCCS)分析,比较2023-2024年度季节性流感疫苗接种后风险窗与对照窗内目标结局的发生率比(IRR)。
  • 研究对象为65岁及以上美国医疗保险受益人,共观察20,258,006名流感疫苗接种者。
  • 使用条件泊松回归估计IRR及95%置信区间,对部分结局调整事件依赖观察时间、季节性及结局错分类不确定性。
  • 对具有统计学显著关联的健康结局,按同期接种状态进行分层分析。

主要发现

  • 过敏反应、脑炎/脑脊髓炎(含ADEM)、吉兰-巴雷综合征、出血性卒中、横贯性脊髓炎未见统计学显著风险升高。
  • 非出血性卒中/TIA复合结局(22-42天风险窗)在接受高剂量疫苗的服务付费人群中IRR为1.07(95%CI 1.01,1.14),在医疗保险优势人群中IRR为1.10(95%CI 1.02,1.17)。
  • 非出血性卒中/TIA复合结局在接受任何流感疫苗的医疗保险优势人群中IRR为1.11(95%CI 1.01,1.22)。
  • 在接受任何流感疫苗的医疗保险优势人群中,个体TIA结局(22-42天风险窗)观察到小的统计学显著风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Influenza vaccination is widely recommended for individuals aged 6 months and older in the United States. While the safety of annual influenza vaccines is well established, FDA conducts routine monitoring and safety evaluations. This study assessed the safety of 2023-2024 influenza vaccines among elderly Medicare beneficiaries. METHODS: A self-controlled case series (SCCS) analysis compared incidence rate ratios (IRR) of anaphylaxis, encephalitis/encephalomyelitis/acute disseminated encephalomyelitis, Guillain-Barré syndrome (GBS), transverse myelitis, hemorrhagic stroke, non-hemorrhagic stroke, transient ischemic attack (TIA), and non-hemorrhagic stroke/TIA, following 2023-2024 seasonal influenza vaccinations in risk and control intervals among Medicare beneficiaries aged 65 years and older. We used conditional Poisson regression to estimate IRRs and 95 % confidence intervals (CIs) adjusted for event-dependent observation time for certain outcomes, seasonality, and uncertainty from outcome misclassification where feasible. For health outcomes with statistically significant associations, we stratified results by concomitant vaccination status. RESULTS: We observed 20,258,006 influenza vaccinees, and no statistically significant elevations of risk for anaphylaxis, encephalitis/encephalomyelitis (with ADEM), GBS, hemorrhagic stroke, or transverse myelitis. For the combined non-hemorrhagic stroke/TIA outcome (22-42-day risk window), we observed a small elevation in risk that was statistically significant in both the Fee-for-Service (IRR: 1.07; 95 % CI: 1.01, 1.14) and Medicare Advantage (IRR: 1.10; 95 % CI: 1.02, 1.17) populations that received a high-dose vaccine. This was also observed among Medicare Advantage beneficiaries that received any influenza vaccine (IRR: 1.11; 95 % CI: 1.01, 1.22). Additionally, we observed a small statistically significant risk for the individual TIA outcome (22-42-day risk window) among the Medicare Advantage population that received any influenza vaccine. CONCLUSION: The benefits of seasonal influenza vaccines established by past studies likely outweigh the risks found in this study. The small, elevated risk of stroke outcomes must be carefully considered in light of the known benefits of influenza vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lloyd PC, Acharya G, Zhao H, et al. Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older. Vaccine. 2025. PMID: 40203591. doi:10.1016/j.vaccine.2025.127069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。